Anti-Asthmatics and COPD Drugs Global Market to 2030 – COVID-19 Implications and Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth” report has been added to ResearchAndMarkets.com’s offering.

This report provides the strategists, marketers and senior management with the critical information they need to assess the demand for anti-asthmatics and COPD drugs market which play a critical role in the treatment of patients with Covid 19.

The global anti-asthmatics and COPD drugs market reached a value of nearly $40,162.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 4.4% since 2015. The global anti-asthmatics and COPD drugs market is expected to grow from $40,162.1 million in 2019 to about $49,384.3 million in 2020 due to an increase in demand for the use of anti-asthmatics and COPD drugs in the treatment of Covid-19 patients.

The global anti-asthmatics and COPD drugs market is expected to grow at a CAGR of 4.1% to nearly $47,176.2 million by 2023. Also, the market is expected to grow to $51,164.1 million in 2025 at a CAGR of 4.1% and to $63,579.9 million in 2030 at a CAGR of 4.4%.

Reasons to Purchase

• Outperform competitors using accurate up to date demand-side dynamics information.
• Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
• Create regional and country strategies on the basis of local data and analysis.
• Stay abreast of the latest customer and market research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Gain a global perspective on the development of the market.

This report describes and evaluates the global anti-asthmatics and COPD drugs market. It covers two five-year periods, one three-year period, and one six-year period including, 2015 to 2019, termed the historic period, and 2019 to 2023 forecast period, 2023-2025 forecast period and 2025 -2030 the forecast period.

Growth in the historic period resulted from increased prevalence of respiratory diseases, increasing incidence of tobacco smoking, global warming, geriatric population, new methods for drug discovery, and rise in healthcare expenditure. Factors that negatively affected growth in the historic period were expiration of patents and political uncertainties.

Going forward, the increased popularity of e-cigarettes/vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats are expected to drive the market. Factors that could hinder the growth of the anti-asthmatics and COPD drugs market in the future include side effects associated with respiratory drugs, reduction in free trade, and stringent regulations.

Key Topics Covered:

1. Anti-Asthmatics And COPD Drugs Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

7. Anti-Asthmatics And COPD Drugs Market Characteristics

8. Anti-Asthmatics And COPD Drugs Market, Supply Chain Analysis

8.1.1. Raw Material And Equipment Procurement

8.1.2. Manufacturing, Processing and Packaging

8.1.3. Distribution

8.1.4. Physicians

8.1.5. End users

9. Anti-Asthmatics And COPD Drugs Market, Product Pipeline Analysis

10. Anti-Asthmatics And COPD Drugs Market, Top 10 Leading Drugs Sales

10.1.1. Ellipta

10.1.2. Spiriva

10.1.3. Symbicort

10.1.4. Advair

10.1.5. Pulmicort

10.1.6. Ventolin

10.1.7. Xolair

10.1.8. Nucala

10.1.9. Flovent

10.1.10. Fasenra

11. Anti-Asthmatics And COPD Drugs Market, Patent Analysis Of Leading Drugs

11.1.1. Background

11.1.2. Innovators

12. Anti-Asthmatics And COPD Drugs Market, Customer Information

12.1. Majority Of Australian COPD Patients Are Physically Inactive And Obese

12.2. Britons Experience Inadequate Treatment Of COPD

12.3. COPD Patients Are More Likely To Be Current Daily Smokers Or Ex-Smokers

12.4. Uncontrolled Asthma Patients Face Recurring Symptoms And Doctor Visits

12.5. Uncontrolled Asthma Patients Struggle With Mobility Issues

13. Impact of COVID-19 On The Anti-Asthmatics And COPD Drugs Market

13.1. Consumer Perception

13.2. High Mortality Among Asthma Patients

13.3. Anti-Asthmatic And COPD Drugs Used In COVID-19 Treatment

14. Anti-Asthmatics And COPD Drugs Market Regulatory Landscape

15. Anti-Asthmatics And COPD Drugs Market Trends And Strategies

15.1. Collaborations In The Anti-Asthmatics and COPD Drugs Market

15.2. Increasing Demand For Personalized Medicines

15.3. Demand For Aerosol Respiratory Drugs

15.4. Use Of Biomarker For Precision Medicine

15.5. Rise Of Generic Respiratory Drugs

15.6. Combination Drug Therapy To Treat COPD

15.7.New Biologic Therapy Medicines To Treat Severe Asthma

16. Asthma And COPD Prevalence Overview

16.1. Asthma

16.2. COPD

17. Global Anti-Asthmatics And COPD Drugs Market Size And Growth

17.1. Market Size

17.2. Historic Market Growth, 2015 – 2019, Value ($ Million)

17.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

18. Anti-Asthmatics And COPD Drugs Market, Regional And Country Analysis

Companies Mentioned

• Abbott Laboratories
• Ache
• Adcock Ingram
• Apotex Inc.
• ASGEN Pharmaceutical Co., Ltd.
• Aspen Nigeria
• AstraZeneca plc.
• Aurobindo Pharma Limited
• Bayer
• Biolab Farmaceuticad
• Boehringer Ingelheim
• Bristol Myers Squibb
• Chiesi Farmaceutici S.p.A.
• China Meheco Group Co., Ltd
• China National Pharmaceutical Group Co., Ltd. (Sinopharm)
• Cipla Limited
• Cipla Medpro South Africa (Pty) Limited
• Cristalia
• Daewoong Pharmaceutical Co., Ltd.
• EMS Pharma
• Eurofarma
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc.
• Hanmi Pharmaceutical
• Hypermarcas
• Jiangsu Hengrui Medicine Co., Ltd.
• Julphar
• KYORIN Holdings, Inc.
• Libbs
• Lupin Limited
• Merck & Co., Inc.
• Mylan
• Neopharma
• Nichi-Iko Pharmaceutical Co., Ltd.
• Novartis
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer
• Sanofi S.A.
• Shanghai Acebright Pharmaceuticals Group Co., Ltd.
• Shanghai Anovent Pharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Teva Pharmaceutical Industries Limited
• Vectura Group

For more information about this report visit https://www.researchandmarkets.com/r/pyma3k

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900